Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors

Journal of Clinical Oncology

Volumn 26, Issue 25, 2008, Pages 4172-4179

  Jimeno, Antonio ^a   Rudek, Michelle A ^a   Kulesza, Peter ^a   Ma, Wen Wee ^a   Wheelhouse, Jenna ^a   Howard, Anna ^a   Khan, Yasmin ^a   Zhao, Ming ^a   Jacene, Heather ^a   Messersmith, Wells A ^a   Laheru, Daniel ^a   Donehower, Ross C ^a   Garrett Mayer, Elizabeth ^a   Baker, Sharyn D ^a   Hidalgo, Manuel ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTEIN P70; RAPAMYCIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANALYTIC METHOD; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT CARCINOMA; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DYSPEPSIA; EDEMA; FATIGUE; FEMALE; FEVER; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCALCEMIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LEUKOPENIA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MODIFIED CONTINUOUS REASSESSMENT METHOD; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROENDOCRINE CANCER; NEUTROPENIA; PAIN; PANCREAS ADENOCARCINOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RASH; SARCOMA; SIDE EFFECT; SINUS CONGESTION; SOLID TUMOR; SORE THROAT; STATISTICAL MODEL; THROMBOCYTOPENIA; TRIACYLGLYCEROL BLOOD LEVEL; TUMOR BIOPSY; URINARY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; SIROLIMUS;

EID: 51649124020     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.2347     Document Type: Article

References (21)

1. Schmelzle T, Hall MN: TOR, a central controller of cell growth. Cell 103:253-262, 2000
2. Thomas G, Hall MN: TOR signalling and control of cell growth. Curr Opin Cell Biol 9:782-787, 1997
3. Garber K: Rapamycin's resurrection: A new way to target the cancer cell cycle. J Natl Cancer Inst 93:1517-1519, 2001
4. Humar R, Kiefer FN, Berns H, et al: Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. Faseb J 16:771-780, 2002
5. Kahan BD: Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation. Transplant Proc 35:S37-S51, 2003
6. MacDonald AS: A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 71:271-280, 2001
7. Zimmerman JJ, Kahan BD: Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 37:405-415, 1997
8. Piantadosi S, Fisher JD, Grossman S: Practical implementation of a modified continual reassessment method for dose-finding trials. Cancer Chemother Pharmacol 41:429-436, 1998
9. Peralba JM, DeGraffenried L, Friedrichs W, et al: Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 9:2887-2892, 2003
10. Young H, Baum R, Cremerius U, et al: Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations: European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35:1773-1782, 1999
11. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
12. Gibaldi M, Perrier D: Pharmacokinetics (ed 2nd). New York, NY, Dekker, 1982
13. Hudes GR, Carducci M, Tomczak P, et al: A phase III, randomized 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J Clin Oncol 24:,2s 2006 (suppl; abstr LBA4)
14. Gibbons JJ, Discafani C, Peterson R, et al: The effect of CCI-779, a novel macrolide anti-tumor agent, on the growth of human tumor cells in vitro and in nude mouse xenograft in vivo. Proc Am Assoc Cancer Res 40, 1999 (abstr 301)
15. Dudkin L, Dilling MB, Cheshire PJ, et al: Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 7:1758-1764, 2001
16. Duran I, Kortmansky J, Singh D, et al: A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 95:1148-1154, 2006
17. Galanis E, Buckner JC, Maurer MJ, et al: Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study. J Clin Oncol 23:5294-5304, 2005
18. Castellvi J, Garcia A, Rojo F, et al: Phosphorylated 4E binding protein 1: A hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 107:1801-1811, 2006
19. Rojo F, Najera L, Lirola J, et al: 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res 13:81-89, 2007
20. Cloughesy TF, Yoshimoto K, Nghiemphu P, et al: Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5:e8, 2008
21. Iwenofu OH, Lackman RD, Staddon AP, et al: Phospho-S6 ribosomal protein: A potential new predictive sarcoma marker for targeted mTOR therapy. Mod Pathol 21:231-237, 2008